Allergy Unit, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy.
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Expert Rev Respir Med. 2021 Aug;15(8):1057-1060. doi: 10.1080/17476348.2021.1917387. Epub 2021 Apr 25.
: The SARS-CoV-2 pandemic has deeply revolutionized our lives and consequently the management of patients, specifically ones with severe asthma.: A survey was conducted to evaluate the effects on adherence, exacerbations and quality of life in patients with severe asthma during the COVID-19 pandemic period.: 100 severe asthma patients, who accepted to participate to the survey, were asked to respond to different questionnaires in order to assess asthma symptoms (Asthma Control Test - ACT, and Asthma Control Quality - ACQ) and rino-sinusal ones (Sino-nasal outcome test - SNOT-22).: 31 out of 100 patients reported worsening of respiratory symptoms requiring a step-up in therapy dosage or frequency during the observational period; however, exacerbation rate was very low. Only 17 (17%) of the 100 participants experienced a severe asthma exacerbation. Moreover, there was no confirmed diagnosis of COVID-19 in this population.: Patients with severe asthma did not show higher rates of exacerbations during the pandemic outbreak as well as no increased risk of contracting COVID-19 infection or developing the disease. Self-administration of biological drugs could be useful to maintain high rates of adherence to therapy, and, at the same time, to decrease the risk of exacerbations or Intensive Care Unit (ICU) room access.
: SARS-CoV-2 大流行深刻地改变了我们的生活，进而改变了患者的管理方式，特别是严重哮喘患者。: 进行了一项调查，以评估 COVID-19 大流行期间严重哮喘患者的依从性、加重和生活质量的变化。: 100 名接受调查的严重哮喘患者被要求回答不同的问卷，以评估哮喘症状（哮喘控制测试 - ACT 和哮喘控制质量 - ACQ）和鼻-鼻窦症状（鼻-鼻窦结局测试 - SNOT-22）。: 31 名患者报告呼吸症状恶化，需要在观察期内增加治疗剂量或频率；然而，加重率非常低。只有 17 名（17%）的 100 名参与者经历了严重哮喘加重。此外，该人群中没有 COVID-19 的确诊病例。: 严重哮喘患者在疫情爆发期间并未出现更高的加重率，也没有更高的 COVID-19 感染风险或患上该病的风险。生物药物的自我给药可能有助于维持较高的治疗依从性，同时降低加重或重症监护病房（ICU）入住的风险。
